Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5263979 | 0.87 | KCNH2 (0.48) | KCNH2SLC2A1 | |
| SCHEMBL3831404 | 0.84 | KCNH2 (0.44) | KCNH2SLC2A1 | |
| SCHEMBL591795 | 0.84 | KCNH2 (0.48) | KCNH2SLC2A1EGFR | |
| SCHEMBL592025 | 0.83 | SLC2A1 (0.47) | KCNH2SLC2A1 | |
| SCHEMBL591064 | 0.83 | SLC2A1 (0.47) | KCNH2SLC2A1 | |
| SCHEMBL591065 | 0.83 | SLC2A1 (0.47) | KCNH2SLC2A1 | |
| SCHEMBL5253770 | 0.82 | KCNH2 (0.44) | KCNH2SLC2A1EGFR | |
| SCHEMBL590211 | 0.82 | KCNH2 (0.47) | KCNH2SLC2A1 | |
| SCHEMBL590212 | 0.82 | KCNH2 (0.47) | KCNH2SLC2A1 | |
| SCHEMBL1712489 | 0.80 | KCNH2 (0.42) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7534793-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2009-05-19 | — | — | US | disclosed |
| US-7491714-B2 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-02-17 | — | — | US | disclosed |
| EP-1567520-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| EP-1359908-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2007-08-22 | — | — | EP | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-20040053928-A1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-18 | — | — | US | disclosed |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
| EP-1359908-A1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003064421-A1 | AMINOPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003064431-A2 | AMINOPIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
| EP-1320529-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-25 | — | — | EP | disclosed |
| EP-1305308-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002056882-A1 | QUINOLINES AND NITROGENATED DERIVAIVE THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002024684-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002008224-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | KCNH2 3440/4885SLC2A1 4727/4885EGFR 2720/4885 |
| US-20040053928-A1 | Quinoline derivatives as antibacterials | AAAS, QDPR, QARS1 | KCNH2 1839/4885SLC2A1 3990/4885EGFR 4635/4885 |
| US-20070161627-A1 | Antibacterial agents | NQO2, NQO1, NDUFV2 | KCNH2 2586/4885SLC2A1 4018/4885EGFR 4632/4885 |
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | KCNH2 2586/4885SLC2A1 4018/4885EGFR 4632/4885 |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | AZI2, AMPD2, AMPD1 | KCNH2 1010/4885SLC2A1 3639/4885EGFR 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.